Breaking News

Nabi Biopharma Earns Fresenius Milestone

Commercial sale of Phoslyra triggers $5M payment

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Nabi Biopharmaceuticals has received a $5 million payment from Fresenius USA Manufacturing, Inc. related to the first commercial sale of Phoslyra, a milestone under an agreement for the company’s 2006 sale of PhosLo (calcium acetate) and related assets to Fresenius. These assets included the rights to a new liquid formulation of PhosLo that Fresenius has commercialized as Phoslyra. Nabi is eligible to receive a $2.5 million milestone for the approval of a new indication for PhosLo along w...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters